Evaluation of the relationship between anti-Müllerian hormone, inhibin-b, testosterone, and semen parameters in cryptorchidism patients

Authors
H. Sadeghipour 1
H. Fanaei 2
I. Halvaei 3
M. A. Sedighi Gilani 4
F. Hajati 5
A. Kasaeian 6
1 (گروه فیزیولوژی) دانشگاه علوم پزشکی تهران
2 Department of Physiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
3 Department of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4 Department of Urology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Anatomical sciences, Faculty of Medical sciences, Tarbiat Modares University, Tehran, Iran
6 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Objective: Cryptorchidism is the most common deficiency of the male reproductive system and most prevalent endocrine disease of boys at birth. Insufficient prenatal anti-Müllerian hormone (AMH) secretion from Sertoli cells of the testis is one of its causes. The role of this hormone and inhibin B in fertility has recently been proven. AMH is a known indicator of Sertoli cell function. The aim of this study was to assess the relationship between anti-Müllerian hormone, inhibin B, testosterone, and semen parameters in post-pubertal cryptorchidism patients.
Methods: We gathered the data of this cross-sectional study from blood and semen samples of 20 patients who had a history of unilateral cryptorchidism. Patients, 20-40 years of age, referred to the Urology Ward of Shariati Hospital, Tehran, Iran. Serum levels of AMH, inhibin B and testosterone were analyzed by enzyme-linked immunosorbent assay. Semen analysis was performed by means of a computer aided semen analysis system 6.5.0. Pearson’s correlation test was used to evaluate the relationships between variables.
Result: Significant positive relationships were existed between total sperm motility and sperm concentration (r=0.086; p<0.01), total motility and fast progressive motility (r=0.97; p<0.01), sperm concentration and fast progressive motility (r=0.9; p<0.01), white blood cell count and sperm concentration (r=0.63; p<0.05), white blood cell count and sperm motility (r=0.66; p<0.05), white blood cell count and sperm fast progressive motility (r=0.77; p<0.01), and testosterone levels and serum AMH (r=0.6; p<0.01).
Conclusion: Cryptorchidism patients in this study had lower serum concentrations of AMH, inhibin B and testosterone than the normal limits. Despite the positive correlation between serum testosterone and AMH, none of the investigated hormones showed any significant relationship with semen parameters.

Keywords

[1]  Adomaitis R, Vincel B, Eidukaite A, Ostaneviciute E, Kirka R, Bilius V, Malcius D, Verkauskas G, Hadziselimovic F. Consequences of bilateral cryptorchidism in adults. Andrologia 2016; 48(9): 933-8.
[2]  Elumalai G, Hariharan A. “Cryptorchidism” Embryological basis and its clinical importance. Elixir Embryology 2017; 102: 44453-8.
[3]  Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C, Edwards R, Richiardi L, Hutson J, Sarfati D. Risk factors for cryptorchidism. Nat Rev Urol 2017; 14(9): 534-48.
[4]  Hamdi SM, Almont T, Galinier P, Mieusset R, Thonneau P. Altered secretion of Sertoli cells hormones in 2-year-old prepubertal cryptorchid boys: a cross-sectional study. Andrology 2017; 5(4): 783-9.
[5]  Braga LH, Lorenzo AJ. Cryptorchidism: A practical review for all community healthcare providers. Can Urol Assoc J 2017; 11(1-2Suppl1): S26-S32.
[6]  Ateş F, Soydan H, Okçelik S, Çırakoğlu A, Yılmaz İ, Malkoç E, Karademir K. Clinical and histopathological results of the adult patients with unilateral cryptorchidism Turk J Urol 2016; 42(2): 74-9.
[7]  Fawzy F, Hussein A, Eid MM, El Kashash AM, Salem HK. Cryptorchidism and Fertility. Clin Med Insights Reprod Health 2015; 9: 39-43.
 
[8]  Osterballe L, Clasen-Linde E, Cortes D, Engholm G, Hertzum-Larsen R, Reinhardt S, Thorup J. The diagnostic impact of testicular biopsies for intratubular germ cell neoplasia in cryptorchid boys and the subsequent risk of testicular cancer in men with prepubertal surgery for syndromic or non-syndromic cryptorchidism. J Pediatr Surg 2017; 52(4): 587-92.
 
[9]  Haid B, Rein P, Oswald J. Undescended testes: Diagnostic algorithm and treatment. Eur Urol Focus 2017; 3(2-3): 155-7.
[10] Bajaj M, Upadhyay V. Age at referral for undescended testes: has anything changed in a decade? N Z Med J 2017; 130(1457): 45-9.
[11] Griffin DL, Cambareri G, Kaplan G. Current practice for cryptorchidism: Survey of pediatric urologists. Urology Practice 2017; 4(3): 245-50.
[12] Rohayem J, Luberto A, Nieschlag E, Zitzmann M, Kliesch S. Delayed treatment of undescended testes may promote hypogonadism and infertility. Endocrine 2017; 55(3): 914-24.
[13] Tseng CS, Huang KH, Pu YS, Chiang IN. The impact of early orchiopexy on undescended testes: Analysis of testicular growth rate ratio. Eur Urol Suppl 2017; 16(3): e1055
[14] Hadziselimovic F. Opinion: Comment on evaluation and treatment of Cryptorchidism: AUA/AAP and nordic consensus guidelines. Urol Int 2016; 96(3): 249-54.
[15] Hutson JM, Lopez-Marambio FA. The possible role of AMH in shortening the gubernacular cord in testicular descent: A reappraisal of the evidence. J Pediatr Surg 2017; 52(10): 1656-60.
[16] oulis DG, Iliadou PK, Tsametis C, Gerou S, Tarlatzis BC, Bontis IN, Papadimas I. Serum anti-Müllerian hormone levels differentiate control from subfertile men but not men with different causes of subfertility. Gynecol Endocrinol 2008; 24(3): 158-60.
[17] Iliadou PK, Tsametis C, Kaprara A, Papadimas I, Goulis DG. The Sertoli cell: Novel clinical potentiality. Hormones (Athens) 2015; 14(4): 504-14.
[18] Komarowska MD, Milewski R, Charkiewicz R, Matuszczak E, Sulewska A, Zelazowska-Rutkowska B, Hermanowicz J, Niklinski J, Debek W, Hermanowicz A. Are anti-Müllerian hormone and its receptor polymorphism associated with the hormonal condition of undescended testes? Adv Med Sci 2016; 61(2): 288-92.
[19] van Brakel J, de Muinck Keizer-Schrama SMPF, Hazebroek FWJ, Dohle GR, de Jong FH. INSL3 and AMH in patients with previously congenital or acquired undescended testes. J Pediatr Surg 2017; 52(8): 1327-31.
[20] Matuszczak E, Hermanowicz A, Komarowska M, Debek W. Serum AMH in physiology and pathology of male gonads. Int J Endocrinol 2013; 2013: 128907.
[21] Weintraub A, Eldar-Geva T. Anti-mullerian hormone (AMH) determinations in the pediatric and adolescent endocrine practice. Pediatr Endocrinol Rev 2017; 14(4): 364-70.
[22] World Health Organization. WHO laboratory manual for the examination and processing of human semen. 5th Edition, Switzerland, Geneva : World Health Organization, 2010.
[23] Brincat D, Catania S, Wismayer PS, Calleja-Agius J. Male factors in ART outcome prediction. Gynecological Endocrinology 2015; 31(3): 169-75.
[24] Grinspon RP, Rey RA. Anti-müllerian hormone and sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr 2010; 73(2): 81-92.
[25] Khazami Pour N, Noruzinia M, Sahebkashaf S, Fatehmanesh P. The role of methylation status of GSTM1 5’UTR in Iranian infertile men with azoospermia Pathobiology Research 2009; 12(1): 43-50. (Persian)
Pathobiology Reserach
Volume 20, Issue 4
December 2018
Pages 67-76